Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages 1290-1297

  Tyrrell, Gregory J ^a,b   Lovgren, Marguerite ^a   St Jean, Theresa ^c   Hoang, Linda ^d   Patrick, David M ^d   Horsman, Greg ^e   Van Caeseele, Paul ^f   Sieswerda, Lee E ^h,i   McGeer, Allison ^g   Laurence, Robert A ^j   Bourgault, Anne Marie ^j   Low, Donald E ^g  

^a PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^b Department of Laboratory Medicine and Pathology ^*  (Canada)

^c Alberta Health and Wellness   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^e Saskatchewan Disease Control Laboratory   (Canada)

^f CADHAM PROVINCIAL LABORATORY   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

^h Thunder Bay District Health Unit   (Canada)

ⁱ NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^j INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG;

ALCOHOL ABUSE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CANADA; CELLULITIS; EPIDEMIC; GROUP A STREPTOCOCCAL INFECTION; HEPATITIS C; HOMELESSNESS; HUMAN; INFECTION RISK; INFECTIOUS ARTHRITIS; MAJOR CLINICAL STUDY; MENINGITIS; NECROTIZING FASCIITIS; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; STREPTOCOCCUS GROUP A; TOXIC SHOCK SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CANADA; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; YOUNG ADULT;

EID: 78649871045     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657068     Document Type: Article

References (30)

1. Fischetti VA. Streptococcal M protein: molecular design and biological behaviour. Clin Microbiol 1988; 2:285-314.
2. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996; 34:953-958.
3. Luca-Harari B, Darenberg J, Neal S, et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009; 47:1155-1165.
4. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008; 14:202-209.
5. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infections and potential vaccine implications, United States, 2000-2004. Clin Infect Dis 2007; 45:853-862.
6. Demers B, Simor AE, Velland H, et al. Severe invasive group A streptococcal infections in Ontario, Canada; 1987-1991. Clin Infect Dis 1993; 16:792-800.
7. Davies HD, McGeer A, Schwartz B, Cann D, Simor A, Low DE; the Ontario Group A streptococcal study group. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996; 335:547-551.
8. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive Group A streptococcal disease in Alberta, Canada, 2000-2002. J Clin Microbiol 2005; 43:1678-1683.
9. Colman G, Tanna A, Efstratiou A, Gaworzewska ET. The serotypes of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease. J Med Microbiol 1993; 39:165-178.
10. Steer A, Law I, Matatolu L, Beall BW, Carapetis J. Global emm type distribution of group A streptococcus: systematic review and implications for vaccine development. Lancet Infect Dis 2009; 9:611-616.
11. Statistics Canada. Estimated population of Canada, 1605 to present. http://www.statcan.gc.ca/pub/98-187-x/4151287-eng.htm#table1. Updated 6 July 2006. Accessed 22 June 2010.
12. Case definitions for diseases under national surveillance-Health Canada. Can Commun Dis Rep 2000; 26(suppl 3):51.
13. Facklam RR, Washington JA. Streptococcus and related catalase-negative gram-positive cocci. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology. 5th ed. Washington, DC, American Society for Microbiology, 1991:238-257.
14. Tyrrell GJ, Lovgren M, Forwick B, Hoe NP, Musser JM, Talbot JA. M Types of group A streptococci isolates submitted to the National Centre for Streptococcus (Canada): 1993-1999. J Clin Microbiol 2002; 40:4466-4471.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard - Ninth edition. CLSI document M2-A9. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 18th Informational Supplement. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
17. Smeesters PR, Vergison A, Campos D, de Aguiar E, Miendjer Deyi VY, van Melderen L. Differences between Belgian and Brazilian group A streptococcus epidemiologic landscape. PLOS One 2006; 1:e10.
18. Espinosa LE, Li Z, Barreto DG, et al. M protein gene type distribution among group A streptococcal clinical isolates recovered in Mexico City, Mexico, from 1991 to 2000, and Durnago, Mexico, from 1998 to 1999: overlap with type distribution within the United States. J Clin Microbiol 2003; 41:373-378.
19. Smeesters PR, Mardulyn P, Vergison A, Leplae R, van Melderen L. Genetic diversity of Group A streptococcus M protein: implications for typing and vaccine development. Vaccine 2008; 26:5835-5842.
20. McGregor KF, Spratt BG, Kalia A, et al. Multilocus sequence typing of Streptococcus pyogenes representing most known emm types and distinctions among subpopulation genetic structures. J Bacteriol 2004; 186:4285-4294.
21. Centers for Disease Control and Prevention. Streptococcus library: emm types as proportions of total disease isolates in six global regions. http://www.cdc.gov/ncidod/biotech/strep/emmtype-proportions.htm. Updated 28 September 2009. Accessed 10 August 2009.
22. Phillips G, Efstratiou A, Tanna A, Beall B, Ferguson J, Roworth M. An outbreak of skin sepsis in abattoir workers caused by an 'unusual' strain of Streptococcus pyogenes. J Med Microbiol 2000; 49:371-374.
23. Dillon HC, Dillon SA. New streptococcal serotypes causing pyoderma and acute glomerulonephritis types 59, 60 and 61. Infect Immun 1974; 9:1070-1078.
24. Lamagni TL, Neal S, Keshishian C, et al. Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004. Clin Microbiol Infect 2008; 14:1002-1009.
25. Sierra JM, Sanchez F, Castro P, et al. Group A streptococcal infections in injection drug users in Barcelona, Spain. Medicine 2006; 85:139-146.
26. Wasserzug O, Valinsky L, Bar-Zeev Y, et al. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis 2009; 48:1213-1239.
27. Sumby P, Porcella SF, Madrigal AG, et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group a Streptococcus evolved in multiple horizontal gene transfer events. J Infect Dis 2005; 192:771-782.
28. Beres SB, Sylva GL, Sturdevant DE, et al. Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections. Proc Natl Acad Sci USA 2004; 101:11833-11838.
29. Ochman H, Lawrence JG, Groisman EA. Lateral gene transfer and the nature of bacterial innovation. Nature 2000; 405:299-304.
30. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962; 89:307-313.